| Primary |
| Pyrexia |
19.8% |
| Nausea |
11.5% |
| Vomiting |
11.5% |
| Acute Myeloid Leukaemia |
10.4% |
| Myelodysplastic Syndrome |
9.4% |
| Pain |
8.3% |
| Leukaemia |
7.3% |
| Acute Lymphocytic Leukaemia |
5.2% |
| Bipolar Disorder |
3.1% |
| Lymphocytic Leukaemia |
3.1% |
| Sleep Disorder |
3.1% |
| Anxiety Disorder |
2.1% |
| Oedema |
2.1% |
| Clostridium Bacteraemia |
1.0% |
| Leukaemia Recurrent |
1.0% |
| Leukaemic Infiltration Brain |
1.0% |
|
| Shock |
17.6% |
| Myalgia |
11.8% |
| Aspartate Aminotransferase Increased |
5.9% |
| Cerebellar Syndrome |
5.9% |
| Dysarthria |
5.9% |
| Hepatocellular Injury |
5.9% |
| Oropharyngeal Pain |
5.9% |
| Pneumonia |
5.9% |
| Pulmonary Toxicity |
5.9% |
| Pyrexia |
5.9% |
| Rash |
5.9% |
| Respiratory Arrest |
5.9% |
| Urinary Incontinence |
5.9% |
| Vomiting |
5.9% |
|
| Secondary |
| Pyrexia |
12.3% |
| Acute Myeloid Leukaemia |
11.4% |
| Prophylaxis |
11.4% |
| Myelodysplastic Syndrome |
10.2% |
| Diffuse Large B-cell Lymphoma |
8.8% |
| Non-hodgkin's Lymphoma |
7.9% |
| Nausea |
6.7% |
| Vomiting |
6.4% |
| Drug Use For Unknown Indication |
4.4% |
| Burkitt's Lymphoma |
2.9% |
| Bipolar Disorder |
2.6% |
| Sleep Disorder |
2.3% |
| Depression |
2.0% |
| Acute Respiratory Distress Syndrome |
1.8% |
| Chemotherapy |
1.5% |
| Fluid Retention |
1.5% |
| Hypertension |
1.5% |
| Multiple Sclerosis |
1.5% |
| Pain |
1.5% |
| Spondylolisthesis |
1.5% |
|
| Febrile Neutropenia |
10.4% |
| Myelodysplastic Syndrome |
10.4% |
| Thrombocytopenia |
10.4% |
| Circulatory Collapse |
8.3% |
| Faecal Incontinence |
8.3% |
| Myalgia |
8.3% |
| Sepsis |
8.3% |
| Gait Disturbance |
4.2% |
| Hepatocellular Injury |
4.2% |
| Leukocytosis |
4.2% |
| Prothrombin Time Prolonged |
4.2% |
| Altered State Of Consciousness |
2.1% |
| Aspartate Aminotransferase Increased |
2.1% |
| Blood Ph Decreased |
2.1% |
| Cardiopulmonary Failure |
2.1% |
| Cytarabine Syndrome |
2.1% |
| Dementia |
2.1% |
| Diabetic Ketoacidosis |
2.1% |
| Diplopia |
2.1% |
| Hepatic Function Abnormal |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
40.6% |
| Neoplasm Malignant |
14.8% |
| Premedication |
14.8% |
| Induction And Maintenance Of Anaesthesia |
9.4% |
| Drug Use For Unknown Indication |
6.0% |
| Anaesthesia |
5.3% |
| Pyrexia |
1.4% |
| Eczema |
1.1% |
| Chemotherapy |
0.9% |
| Nausea |
0.9% |
| Vomiting |
0.9% |
| Diffuse Large B-cell Lymphoma |
0.8% |
| Pain |
0.7% |
| Acute Myeloid Leukaemia |
0.6% |
| Myelodysplastic Syndrome |
0.6% |
| Intravenous Catheter Management |
0.3% |
| Anxiety |
0.2% |
| Bipolar Disorder |
0.2% |
| Chronic Myeloid Leukaemia |
0.2% |
| Gastric Disorder |
0.2% |
|
| Hyperthermia |
52.3% |
| Vomiting |
21.9% |
| Nausea |
11.3% |
| White Blood Cell Count Increased |
2.0% |
| Myelodysplastic Syndrome Transformation |
1.3% |
| Tachycardia |
1.3% |
| Weight Decreased |
1.3% |
| Anxiety |
0.7% |
| Chronic Myeloid Leukaemia Transformation |
0.7% |
| Coagulopathy |
0.7% |
| Death |
0.7% |
| Headache |
0.7% |
| Leukaemia Recurrent |
0.7% |
| Metabolic Disorder |
0.7% |
| Mucosal Inflammation |
0.7% |
| Plasmablastic Lymphoma |
0.7% |
| Product Substitution Issue |
0.7% |
| Rash |
0.7% |
| Reversible Posterior Leukoencephalopathy Syndrome |
0.7% |
| Road Traffic Accident |
0.7% |
|
| Interacting |
| Acute Myeloid Leukaemia |
37.5% |
| Anxiety Disorder |
12.5% |
| Nausea |
12.5% |
| Oedema |
12.5% |
| Pain |
12.5% |
| Vomiting |
12.5% |
|
|
